争议事件
以下收录公开来源中与该品牌相关的争议事件。列出一条并不表示过错已经证实。
返回词条共 4 条
2024
法院允许艾尔建针对Revance的商业秘密主张继续审理
裁决
在艾尔建针对竞争对手Revance提起的商业秘密诉讼中,法院驳回了Revance的驳回动议,认为有关获取商业秘密及产品相似性的指控足以支持案件继续审理。这些仍是指控,并非责任认定。
来源摘录
The court inferred use of the trade secrets based on access and similarity.
District Judge Eli Richardson disagreed, denying Revance’s motion to dismiss.
2022
Teva与Allergan就旧金山阿片类药物诉讼达成和解
和解
Teva Pharmaceutical Industries与AbbVie旗下Allergan部门就被指助长旧金山阿片类药物流行一事,达成总额5800万美元的和解。Teva将支付2500万美元并提供价值2000万美元的Narcan,AbbVie将支付1300万美元。Teva与Allergan均未承认有不当行为。
当事方说明的目的. 解决相关索赔并避免下个月开庭审理。
品牌回应
否认 — CVS Health Corp, Teva Pharmaceutical Industries Ltd, Abbvie Inc's Allergan unit, and Endo International Plc
The four companies denied wrongdoing in agreeing to settle.
来源摘录
Neither Teva nor Allergan admitted wrongdoing as part of the settlement
Under the deal announced by City Attorney David Chiu, Israel-based Teva will pay $25 million in cash and contribute a $20 million supply of the overdose-reversal drug Narcan. AbbVie will pay $13 million.
The four companies denied wrongdoing in agreeing to settle.
2022
明尼苏达州等州与 Allergan 达成阿片类药物暂定和解
和解
明尼苏达州总检察长 Keith Ellison 宣布,多个州已与 Allergan 达成总额 23.7 亿美元的暂定和解协议,最终条款仍待敲定。Ellison 指称,相关公司将利润置于民众生命之上,造成死亡与伤害。
来源摘录
Friday morning, Minnesota Attorney General Keith Ellison announced multiple states had reached a tentative $2.37 billion agreement with Allergan.
Even so, I have and will continue to aggressively hold these companies accountable for the harm they’ve caused in order to protect the people of Minnesota.
Drug manufacturer Allergan has agreed to pay Suffolk and Nassau counties and the state of New York up to $200 million for its role in the opioid epidemic.
2018
阿片类药物相关诉讼
艾尔建与其他制药制造商和分销商一起,在美国各州和市政当局就阿片类药物流行提起的诉讼中被点名。诉讼涉及在阿片类药物的制造、营销或分销中的所谓角色;诉讼程序构成了更广泛的全国性阿片类药物诉讼的一部分。